multiple repeats in apo (a) . The number of repeats varies and is under genetic control, giving rise to different sizes of apo(a) and, consequently, of Lp(a), the size being inversely related to the Lp(a) concentration in plasma (1) . Clinical studies have shown that increased concentrations of Lp(a) are associated with coronary and cerebrovascular disease. These findings suggest a possible molecular mechanism for the association of Lp(a) concentrations and atherosclerosis and have been a tremendous stimulus to further research into the genetics, metabolism, and disease association of Lp(a) . This has resulted in increased interest in the measurement of Lp(a) . Because of complexity and heterogeneity of the protein structure of Lp(a) and the homology of apo(a) with plasminogen, a careful examination of the imniunochemical properties of Lp(a) and a common approach for the standardization and expression of its measurements are required. In this review we identify the problems related to immunochemical measurements of Lp(a) , to aid clinical chemists in evaluating the suitability of available methods.
Historical Perspective
Genetic antigenic variations of human serum beta lipoprotein were discovered in 1961 (2) . The serum of a multiply transfused patient was found to precipitate with some but not all normal sera. The antigen identified by the patient's isoimmune serum was beta lipoprotein, which was found to be genetically determined independent of other known marker systems. This system was called the Ag system. An LDL allotype system, analogous to the Ag system and called Lpq, has also been described in the rabbit (3, 4) . In 1963, Berg (5) attempted to demonstrate individual antigenic differences in human beta lipoproteins by immunizing rabbits with a human LDL fraction. These heteroimmune sera, absorbed with LDL, detected an antigen in some but not all individuals.
This new system was given the name Lp, referring to lipoprotein; positive reactors were designated Lp(a+), and negative reactors Lp(a-).
At this time the Lp(a) antigen was identified as belonging to the lipoproteins of the density class 1019-1063 g/L (6).
Family studies indicated that the Lp(a) antigen was genetically determined, and Lp(a) was found in 30% to 40% of the subjects studied in different populations (7) . Thus, the Lp(a) was considered to be a qualitative genetic trait and a genetic variant of LDL.
Chemical studies of the Lp(a) lipoprotein in the early 1970s indicated that, although the lipid composition was similar to that of LDL, the lipoprotein containing the Lp(a) antigen contained significantly more carbohydrate than did LDL and, unlike LDL, had pro-beta mobility (8) . Upon ultracentrifugation of serum, the very-low-density pro-beta lipoproteins float but Lp(a) sinks; thus, Lp(a) became referred to as the "sinking pre-beta lipoprotein" (9) . Furthermore, the lipoprotein carrying the (a) antigen was also 0.4-0.5
Lipoprotein(a) (g/L) found in the high-density lipoprotein (HDL) fraction of 1060-1120 g/L (10) (11) (12) (18) (19) (20) .
The distribution of Lp(a) concentrations in plasma is highly skewed, as shown in Figure 1 (17-20) . The distribution of Lp(a) concentrations in blacks is less highly skewed; moreover, these concentrations are significantly higher in blacks than in whites (21, 22 Lp(a) standards, and the lack of common reference materials.
Metabolism of Lp(a)
Quantitative imniunochemical precipitation of iss1 labeled Lp(a) particles indicates that nearly all apo(a) is associated with ape B (17) . After disulfide reduction, apo(a) is readily dissociated from Lp(a), and the remaining lipoprotein particle, containing ape B-100, is very similar to LDL (25,26). Despite some structural similarities and the fact that they both share ape B-100, Lp(a) and LDL are metabolically distinct lipoproteins. Unlike LDL, Lp(a) does not appear to be a byproduct of VLDL metabolism (27) Lp(a) binds to the LDL receptor with an affinity similar to that of LDL and that clearance of human Lp(a) is markedly increased in transgenic mice that overproduce human LDL receptors (42). Despite the conflicting data, the LDL receptor probably is involved in the clearance of Lp(a).
Lp(a), Coronary Disease, and Thrombosis
Nearly 25 years ago, Renninger eta!. (43) recognized the positive association of Lp(a) have a mean Lp(a) concentration two to three times the mean of a healthy control group (41). Among subjects with familial hypercholesterolemia, those with coronary disease have significantly higher Lp(a) concentrations than do those without coronary disease (55) . Thus, increased Lp(a) is a strong risk factor for coronary heart disease in patients with familial hypercholesterolemia.
Physicochemical Heterogeneityof Lp(a)
Lp(a) particles exhibit considerable inter-and intraindividual density heterogeneity, with some individuals exhibiting two or more distinct Lp(a) particles differing in hydrated density (16) . Also, the Lp(a) particle varies widely in size, with the size heterogeneity related primarily to the different sizes of the apo(a) isoforms, ranging from 280 to 838 kDa (1, 56). The isoforms are identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by immunoblotting with polyclonal or monoclonal antibodies specific for Lp(a). Most individuals have one or two ape(a) isoforms, although in some subjects an apo(a) band cannot be detected. The number of isoforms that can be distinguished varies from six (1) to at least 12 isoforms (56). The major isoforms are believed to be specified by different alleles at the structural gene locus for apo(a) (1, 57, 58). The frequencies of the single-band phenotypes, as determined by Utermann (1) in a healthy Austrian population, are shown in Figure 2 . The smaller isoforms are generally present at less frequency and are associated with the higher Lp(a) concentrations, whereas the larger isoforms have a higher frequency and are associated with lower Lp(a) Lp(a) concentrations are highly skewed in the Caucasian population.
As seen in Figure 2 , there is a significant inverse relationship between the apparent molecular mass of the ape(a) isoforms and the concentration of Lp(a) in plasma.
The structural gene for apo(a) is located on chromosome 6 at a locus closely linked to the plasminogen gene (59). Apo(a), which has a high structural homology with plasminogen (Figure 3) although it is believed that most Lp(a) particles contain a single copy of ape B-100 and a single copy of apo(a). However, some data suggest that some Lp(a) particles may contain two copies of apo(a) (64).
Lp(a) and Fibrinolysis
Recent studies have suggested that increased Lp(a) concentrations may inhibit fibrinolysis by reducing the generation of plasmin.
Lp(a) may reduce the generation of plasmin by various mechanisms:
(a) competing for plasminogen cell-surface receptors (65) (66) (67) of dedicated instruments, the skill of the technologist, the required turnaround time, and the cost per analysis. Radial immunodiffusion was one of the first methods to be developed for measuring
Lp(a) in human plasma (19).
This method is relatively easy to perform, does not require dilution of the samples, and can be used with pelyclonal antibodies or a mixture of defined monoclonal antibodies (79, 80) . However, besides its unsuitability for screening large populations and its relative insensitivity, the major problem of this method is its sensitivity to the differences in size of the analyte being measured (81) . Thus, the different sizes of Lp(a) can lead to technical artifacts, with the smaller size Lp(a) particles potentially overestimated and the larger particles underestimated. The immunonephelometric and the immunoturbidimetric assays are most suitable for the clinical laboratory, in that they have a high throughput, do not require isotopes, and are easy to perform. However, the nephelometric method also is highly sensitive to differences in size of the analyte being measured, owing to different amounts of light scattering per particle. For example, the measurement of ape B can be inaccurate in samples containing large, triglyceride-rich particles (82) , because the lightscattering of these large particles differs from that for the LDL particles in the calibrator.
Thus, the effect of the differences in size of the Lp(a) particles on the accuracy of Lp(a) concentrations measured by nephelometric assays needs to be carefully evaluated.
Theoretically, if the calibrator contains all major ape(a) isoforms, the magnitude of the problem would be reduced.
Radioimmunoassay is a highly sensitive technique, can be fully automated, and can be developed with pelyclonal or monoclonal antibodies. However, it requires dedicated equipment, the measurement of the analyte in duplicate or triplicate to achieve satisfactory precision, and the use of radioisotopes, which have limited shelf life. Furthermore, if a fluid-phase competitive radioimmunoassay is used, repeated purification of Lp(a) from human plasma is required because of the short-term stability of Lp(a) in isolated form.
The enzyme-linked immunosorbent assay (ELISA) method has the same advantages and disadvantages as radioimmunoassay, except that no radioisotopes are required. At present, ELISA is the most commonly used technique to measure Lp(a). Most of the ELISA5 for Lp(a) are based on the noncompetitive direct binding two-step "sandwich" format rather than the competitive format. This approach eliminates the need to bind purified Lp(a) to microtiter plates, which can lead to artifacts attributable to diminished epitope recognition (83) . Alteration of epitope expression as a result of adsorption of a lipoprotein to plastic has also been reported for LDL, and presumably involves induction of conformational changes in the lipoprotein upon binding to plastic (84) .
Until recently, quantitative immunochemical determinations of Lp(a) were based exclusively on the use of polyclonal antibodies raised against isolated Lp(a) particles. To eliminate cross-reactivity with ape B, the antisera were immunoabsorbed with LDL, making the assays specific for apo(a). However, because of the high degree of homology of apo(a) with plasminogen, as was recently discovered (60) (61) (62) (63) , one must demonstrate that the antibodies used to measure apo(a) do not cross-react with plasminogen. Some authors, to eliminate this cross-reactivity, developed ELISA methods in which antibodies against ape(a) were used as capture antibodies and antibodies against apo B-100 as detecting antibodies (64, 71 
Calibration of the Immunoassays
The accuracy and standardization of the iminunoassays depend on the availability of suitable primary standard, reference material, and calibrator. A key step for the accuracy is the preparation of appropriate primary standard to be used to transfer the value to a common reference material and from the reference material to the calibrators of the different immunoassays. Delipidated Lp(a) undergoes a high degree of self-association and irreversible aggregation and therefore is not suitable as a primary standard. As yet, there is no recommendation on a standard protocol for isolation of Lp(a) to be used as primary standard. Lp(a) is often isolated from the 1050-1120 g/L density fraction of plasma (10) . Subsequent to ultracentrifugation, Lp(a) is commonly separated from other lipeproteins by gel filtration (19) . Isolation of Lp(a) by a combination of ultracentrifligation and gel filtration results in low recoveries of Lp(a) (15-20%), but the reason for these losses is unclear. To minimize contamination of Lp(a) with non-Lp(a) apelipoproteins, some researchers have isolated Lp(a) from the HDL density range of 1060-1090 g/L (9, 17, 19) . However, Lp(a) of this selected density range may not be representative of the composition of the total Lp(a) in plasma. Furthermore, the smaller Lp(a) particles of low density appear to be relatively stable, but the larger particles of high density tend to precipitate at low temperature (16,64, 
86).
A different approach for the isolation of Lp(a) involves the use of specific immunoabsorbents or anti-apo(a) affinity chromatography.
The current availability of monoclonal antibodies specific for ape(a) is particularly attractive for this approach. Lp(a) has also been isolated by rate zonal gradient centrifugation (16). This approach offers the advantage of separating the different density populations of Lp(a), but usually requires an additional affinity chromatography step to ensure purity. The use of lysine-Sepharose affinity chromatography for Lp(a) isolation has also been reported (60); however, only part of the total Lp(a) in plasma is obtained by this approach.
Another approach for the preparation of a primary standard is the use of purified ape(a). Ape(a) can be isolated from Lp(a) by reduction of the disulfide bonds and centrifugation to remove ape B and lipid (16) or may be synthesized by bioengineering techniques. Before apo(a) can be used as a primary standard, it must be demonstrated to behave immunochemically the same as apo(a) in the native Lp(a) particle in the method selected. Monoclonal antibodies prepared against purified apo(a) have been shown to react poorly with intact Lp(a) particles (83) , whereas others prepared against intact Lp(a) react poorly with apo(a) (87) ; this suggests that some antigenic determinants are sensitive to disulfide bond reduction. Therefore, biosynthesized ape(a) containing intact disulfide bonds would more probably express the epitopes of native Lp(a) than of ape(a) after reduction.
What is needed from a primary standard is the ability to determine its absolute mass by independent chemical methods to establish the basis of a calibration system. Historically, Lp(a) concentrations have been expressed in terms of total lipeprotein mass (17, 19, 24) . However, obtaining an accurate and reproducible determination of Lp(a) particle mass in the primary standard is difficult because it requires summation of the independent determination of the Lp(a) constituents-protein, lipid, and carbohydrate-and because the chemical composition of Lp(a) is quite variable. For these reasons, the expression of Lp(a) in terms of total particle mass should be discouraged. Several approaches have been used to determine the absolute protein mass of Lp(a), including micro Kjeldahl, Lowry protein analysis with or without sodium dodecyl sulfate, and amino acid analysis. Although the total protein mass of the Lp(a) particle can be estimated by amino acid analysis by summation of all amino acids, such an approach is expensive and time-consuming and would require independent determinations of cysteine and tyrosine, in addition to corrections for losses of some of the unstable amino acids during hydrolysis. For macromolecular complexes containing a single protein such as LDL, in which the primary sequence is known, the absolute mass can be calculated on the basis of only those amino acids that are known to be stable and completely recovered (88 Lp(a) species containing a representative distribution of the different isoforms should minimize the potential differences of measured Lp(a) particle concentration that reflect differences in immunoreactivity of the different species rather than differences in particle mass.
To achieve harmonization of the data obtained by the different methods requires suitable reference material with a properly assigned target value through the use of a primary standard. The material must not exhibit matrix interactions between methods, must reflect the immunechemical characteristics of a patient's specimen, and must be stable (89) . Serum pools in lyophilized form are not a suitable matrix for reference materials for apo B measurements (90). Therefore, before anyone proposes a reference material for Lp(a) measurements, the characteristics of lyophilized material should be carefully evaluated and compared with those of frozen and fresh serum in the different systems.
Conclusions
Lp(a) values are expressed in terms of particle mass, total protein, or arbitrary
units. An understanding of the problems related to the complexity of Lp(a) is essential for the standardization of the immunochemical methods used for its determination.
Common reference materials and a standardized protocol for the preparation of primary standards for Lp(a) measurement
are not yet available. A common approach to the standardization of Lp(a) determination should be followed, similar to the steps taken to standardize measurements of ape B and ape A-I (89) . The Committee on Apolipoproteins of the Scientific Division of the International Federation of Clinical Chemistry is at present working very actively on the standardization of apolipoproteins A-I and B with 25 major diagnostic companies that manufacture test systems for measuring ape A-I and B. The objectives of the study are to evaluate the differences between calibration in the different systems, to obtain uniformity of the data with the use of frozen serum pools as reference materials, and to evaluate and select candidate international reference materials prepared and proposed by several companies. The results of the first phase of the study (unpublished) have shown that the use of fresh-frozen serum pools as common reference materials leads to good agreement among the different systems. An average CV of 5% for apo A-I and 6% for ape B among 26 and 28 systems, respectively, was obtained for assay of 10 normotriglyceridemic samples. A study on further evaluation of selected candidates for an international reference material is in progress.
The problems related to the matrix interaction of reference materials for ape B measurements may differ from those for Lp(a) measurements. Most of the actions to solve the problems of standardization of Lp(a)-e.g., a common protocol for isolation of the primary standard; the selection of the Lp(a) moiety to be measured; the selection of the ape(a) isoform(s) in the primary standard, reference material, and calibrator; the evaluation of suitable international reference material; and the expression of the results-can only be taken by a consensus. The formation of a working group consisting of experts with a long-standing involvement in the problems of Lp(a) measurement is necessary to provide a platform for standardization.
It is important that investigators agree on a common approach to define and express Lp(a) values, and that a common reference material be used to harmonize the data, thereby permitting a direct comparison of the numerous approaches to measure Lp(a).
